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Abstract
Purpose—MERTK tyrosine kinase is ectopically expressed in 30–50% of acute lymphoblastic 
leukemias (ALL) and over 80% of acute myeloid leukemias (AML) and is a potential therapeutic 
target. Here, we evaluated the utility of UNC2025, a MERTK tyrosine kinase inhibitor, for 
treatment of acute leukemia.
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Experimental Design—Pre-clinical in vitro and in vivo assays using cell lines and primary 
leukemia patient samples were utilized to evaluate anti-leukemic effect of UNC2025.
Results—UNC2025 potently inhibited pro-survival signaling, induced apoptosis and reduced 
proliferation and colony formation in MERTK-expressing ALL and AML cell lines and patient 
samples. Approximately 30% of primary leukemia patient samples (78 of 261 total) were sensitive 
to UNC2025. Sensitive samples were most prevalent in the AML, T-ALL, and minimally 
differentiated (M0) AML subsets. UNC2025 inhibited MERTK in bone marrow leukemia cells 
and had significant therapeutic effects in xenograft models, with dose-dependent decreases in 
tumor burden and consistent two-fold increases in median survival, irrespective of starting disease 
burden. In a patient-derived AML xenograft model, treatment with UNC2025 induced disease 
regression. Additionally, UNC2025 increased sensitivity to methotrexate in vivo, suggesting that 
addition of MERTK-targeted therapy to current cytotoxic regimens may be particularly effective 
and/or allow for chemotherapy dose reduction.
Conclusions—The broad spectrum activity mediated by UNC2025 in leukemia patient samples 
and xenograft models, alone or in combination with cytotoxic chemotherapy, support continued 
development of MERTK inhibitors for treatment of leukemia.
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Introduction
Chemotherapy dose intensification has improved survival in acute leukemia. However those 
with certain cytogenetic abnormalities or relapsed/refractory disease continue to have a poor 
prognosis. Additionally, intensive cytotoxic regimens often lead to life-long toxicities (1–4) 
and are contraindicated in elderly patients due to significant mortality (5, 6). Thus, new 
approaches are needed.
MERTK is a receptor tyrosine kinase that is ectopically expressed in 30–50% of acute 
lymphoblastic leukemias (ALL) (7–9) and over 80% of acute myeloid leukemias (AML) 
(10) and Gas6, a MERTK ligand, has been associated with poor prognosis in AML patients 
(11). In leukemia cells, MERTK regulates components of downstream signaling pathways 
that promote tumor cell proliferation and survival, including JAK/STAT, MEK/ERK, p38, 
PKC, and AKT (7, 9, 10). MERTK transgenic mice develop B- and T-cell leukemias (12) 
and shRNA-mediated inhibition in ALL and AML cell lines results in delayed 
leukemogenesis and prolonged survival in orthotopic xenograft models (7, 9, 10). 
Additionally, inhibition of MERTK sensitizes leukemia cells to cytotoxic chemotherapies (7, 
9) and treatment with Gas6 promotes chemoresistance (13), suggesting MERTK inhibition 
may improve response to chemotherapy and/or allow dose reduction.
While several tyrosine kinase inhibitors (TKIs) have some activity against MERTK, most 
target other kinases (14). To more potently and selectively inhibit MERTK, we developed 
UNC2025, an orally-bioavailable small molecule TKI with properties suitable for clinical 
application (15). UNC2025 inhibits MERTK in enzymatic and cell-based assays, with Ki 
DeRyckere et al. Page 2
Clin Cancer Res. Author manuscript; available in PMC 2018 March 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and IC50 values of 0.16 and 2.7nM, respectively. The compound has similar activity against 
FLT3 and may be particularly well-suited for treatment of AML where FLT3 is a well-
characterized therapeutic target. UNC2025 is selective for MERTK and FLT3, with only 66 
of 305 kinases inhibited by >50% at concentrations >100X the MERTK IC50 and >45-fold 
selectivity for MERTK relative to Axl, the next most potently inhibited kinase (Ki = 13.3nM 
and IC50 = 122nM). UNC2025 also has pharmacokinetic properties suitable for in vivo 
studies, including low clearance, a 3.8-hour half-life in mice, 100% oral bioavailability, and 
high solubility in saline (15). Most importantly, orally-administered UNC2025 inhibits 
MERTK in bone marrow leukemic blasts for up to 24 hours. Here we describe preclinical 
studies demonstrating therapeutic effects of UNC2025 in acute leukemia patient samples 
and animal models supporting further clinical development.
Methods
Cell lines and patient samples
Cell lines were obtained, cultured and identities confirmed as previously described (7, 9, 10). 
De-identified apheresed patient samples were obtained from University of Colorado after 
informed consent with approval from the Colorado Multiple Institutional Review Board 
(IRB) and maintained as previously described (16). De-identified cord blood and normal 
bone marrow samples were obtained commercially from Clinimmune Labs and 
ALLCELLS, respectively.
Immunoblot analysis
Leukemia cells (3x106/mL) were cultured with UNC2025 or DMSO equivalent to 300nM 
UNC2025 for one hour. Cell lysates were prepared and signaling proteins were detected by 
immunoblot (antibodies listed in Supplemental Table 1) (15). Cells were treated with 
pervanadate and MERTK was immunoprecipitated to detect phosphorylated MERTK (15).
Apoptosis, cell cycle, and colony formation assays
Cells were cultured (3x105/mL) for 6, 24, and/or 48 hours with UNC2025 or DMSO. 
Apoptotic and dead cells were detected by flow cytometry after staining with YO-PRO-1-
iodide and propidium-iodide (7), cell cycle profiles were determined by assessment of 
propidium iodide staining in permeabilized cells using flow cytometry(17), and MTT 
reduction was determined as an indicator of viable cell number(17). Alternatively, ALL cell 
lines and patient samples were cultured in methylcellulose after treatment (10). AML cell 
lines were cultured in 0.35% Noble agar overlaid with medium containing UNC2025 or 
vehicle (15). Human mononuclear cells from normal bone marrow or umbilical cord blood 
were cultured in methylcellulose containing UNC2025 or DMSO (18). Colonies were 
counted after 7 (normal marrow) or 14 (umbilical cord blood, cell lines and patient samples) 
days.
Patient sample sensitivity screening
Blood and bone marrow samples were obtained after informed consent with IRB approval at 
Oregon Health & Science University, Stanford University, University of Utah, UT-
Southwestern and University of Colorado-Denver. Mononuclear cells were cultured for 72 
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hours in 384-well plates with graded concentrations of UNC2025 or vehicle and relative 
numbers of viable cells were determined (19). IC50 values were calculated by non-linear 
regression.
Leukemia xenograft models
697 cells, monoclonal 697 cells expressing firefly luciferase (20), NOMO-1 cells, or 
mononuclear cells from an AML patient sample (2x106/mouse) were injected into the tail 
vein in NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) or NOD.Cg-PrkdcscidIl2rgtm1WjlTg(CMV-
IL3,CSF2,KITLG)1Eav/MloySzJ (NSGS) mice. Disease burden was monitored in 697-
luciferase xenografts using bioluminescence imaging (21). Peripheral blood, spleen, and 
bone marrow were collected from patient-derived xenografts and red blood cells (RBCs) 
were lysed in 50% Dextran sulfate for 15 minutes. Human CD45+ cells were detected using 
flow cytometry. Mice were distributed to groups with statistically equal disease burden or 
randomized to groups if leukemia was undetectable. UNC2025 or saline was administered at 
10ml/kg once daily by oral gavage. Methotrexate or saline was administered at 5ml/kg by 
intraperitoneal injection. Mice with advanced leukemia (>20% weight loss, tachypnea, 
hypothermia, hind-limb paralysis, minimal activity) were euthanized and survival was 
monitored. Pharmacodynamic studies were performed as previously described (15). Animal 
experiments were conducted in accordance with regulatory standards as approved by the 
University of Colorado Institutional Animal Care and Use Committee (Protocol 
#B-66912(12)1E).
Analysis of hematopoietic precursors and peripheral blood counts
C57Bl/6 mice were treated with UNC2025 or saline daily for 24 days. Peripheral blood was 
collected into EDTA-coated tubes and complete blood counts were determined using a CBC-
Diff Hematology Analyzer (HESKA). Bone marrow cells isolated from leg bones were 
stained and quantitated using a Gallios flow cytometer (Beckman Coulter) and FlowJo vX 
software (see Supplemental Table 1) (7).
Statistics
Statistical analyses were performed using GraphPad Prism software (v6.02). Mean values 
and standard errors are reported. When only two cohorts were compared, data were analyzed 
using an unpaired t-test. All other data were analyzed using one-way ANOVA with 
Bonferroni’s multiple comparisons correction. Differences were considered significant when 
p<0.05.
Results
UNC2025 inhibits MERTK signaling, induces apoptosis, inhibits proliferation, and 
decreases colony-formation in MERTK-expressing acute leukemia cell lines
MERTK-expressing B-cell and T-cell acute lymphoid leukemia (B-ALL and T-ALL) and 
acute myeloid leukemia (AML) cell lines (Figure 1A) were used to determine the effects of 
UNC2025. Notably, none of the cell lines or patient samples described here have FLT3 
activating mutations, therefore observed effects are likely due to MERTK inhibition.
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697 B-ALL and Kasumi-1 AML cells were cultured with UNC2025 or vehicle for one hour 
and phospho-proteins were analyzed. UNC2025 mediated potent and dose-dependent 
decreases in MERTK phosphorylation/activation in both cell lines (Figure 1B) and inhibition 
of MERTK correlated with decreased phosphorylation of previously reported MERTK-
dependent signaling components STAT6, AKT, and ERK1/2 (Figure 1C).
To investigate functional effects of UNC2025-mediated MERTK inhibition, ALL and AML 
cell lines were cultured with UNC2025 or vehicle for 48 hours, stained with YO-PRO-1 
iodide (YoPro) and propidium iodide (PI) dyes, and analyzed by flow cytometry to identify 
early apoptotic (YoPro+, PI negative) and late apoptotic or dead (YoPro+, PI+) cells or 
permeabilized and stained with propidiuim iodide, then analyzed by flow cytometry to 
determine cell cycle profiles. UNC2025 induced dose-dependent cell death in B-ALL (697, 
REH), T-ALL (Jurkat), and AML (Kasumi-1, NOMO-1) cell lines (Figure 1D and 
Supplemental Figures 1A and B). Cell death was induced in 25–90% of cells after 48 hour 
treatment with 200–300nM UNC2025, corresponding with near complete MERTK 
inhibition (Figure 1B). Treatment with 200–300nM UNC2025 also altered cell cycle 
progression with significant decreases in the fraction of cells in G0/G1 phases evident as 
early as 6 hours post-treatment and more substantial changes after 24–48 hours, including 
accumulation of cells in G2/M phases (15–94% of cycling cells versus 12–24% in vehicle-
treated cultures) and decreased cells in S phase (2–28% of cycling cells versus 21–45% in 
vehicle-treated cultures) in all 5 cell lines (Figure 1E, Supplemental Figures 1C, E, and F, 
and Supplemental Table 2). In addition, polyploidy was induced in Jurkat T-ALL and 
NOMO-1 AML cells. These data demonstrate altered cell cycle progression and are 
indicative of decreased tumor cell proliferation in response to treatment with UNC2025. 
Together, decreased tumor cell survival and proliferation led to significantly reduced 
numbers of viable cells in cultures treated with UNC2025 (Supplemental Figure 1D).
Colony-forming potential was determined to further assess the impact of UNC2025 on 
oncogenic phenotypes. AML cell lines were cultured in soft agar overlaid with medium 
containing UNC2025 or vehicle..ALL cell lines were treated with UNC2025 or vehicle for 
48 hours and equal numbers of viable cells were cultured in methylcellulose. UNC2025 
mediated significant, dose-dependent decreases in colony formation in all cell lines tested 
with a >50% reduction at 200nM in 3 of 5 cell lines tested in response to treatment with 
100nM UNC2025 and near complete abrogation of colony growth in 4 of 5 lines at a dose of 
300nM (Figure 1F).
UNC2025 inhibits MERTK signaling and colony-forming potential in a MERTK-expressing 
patient sample
Similar assays were performed using a MERTK-expressing (AML-123009) primary patient 
sample. UNC2025 decreased phosphorylation of MERTK and downstream signaling 
proteins STAT6, AKT, and ERK1/2 (Figures 2A and B). Decreased colony-formation was 
evident at concentrations as low as 25nM, with >90% inhibition at 300nM (Figure 2C). In 
contrast, mononuclear cells isolated from normal human cord blood or bone marrow, which 
express very little or no MERTK (7, 10), were resistant to UNC2025 at doses <500nM 
(Figure 2D). These data demonstrate selective anti-leukemia effects mediated by UNC2025 
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in a MERTK-expressing patient sample with a 20-fold difference in sensitivity of MERTK-
expressing leukemia blasts relative to normal cord or marrow blood mononuclear cells, 
suggesting a large therapeutic window.
UNC2025 inhibits expansion of leukemia patient samples in culture
To better characterize effects of UNC2025 in primary samples, expansion of freshly-isolated 
leukemia cells was assessed using a high-throughput assay. Bone marrow and peripheral 
blood mononuclear cells from leukemia patients were cultured with UNC2025 or vehicle for 
72 hours and the concentration of UNC2025 required to decrease viable cells by 50% (IC50) 
was calculated. A total of 261 individual samples were analyzed and >60% were collected 
from patients at first diagnosis. IC50 values ranged from 9.0nM to >10μM with a median 
IC50 of 2.38μM (Figure 2E). Sensitivity to UNC2025 was determined relative to the median 
IC50, with values <475nM (20% of the median) and 238nM (10% of the median) scored as 
sensitive and very sensitive, respectively. Using this method, 30% of samples (78 of 261) 
were sensitive and >75% of these (59 of 78) were very sensitive. Sensitive AML, B-ALL, T-
ALL, chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML) samples 
were identified with the greatest percent of sensitive samples in the AML (40%) and T-ALL 
(50%) subsets. Although the T-ALL subset was small, all four samples tested had IC50 
values below the median. In the AML subset, sensitivity to UNC2025 was similar in patient 
samples with and without an activating FLT3 mutation (Supplemental Figure 2). Further 
subcategorization demonstrated that FAB classification M0 (minimally differentiated) AML 
samples were consistently particularly sensitive with IC50 values <70nM (Figure 2F). In 
contrast, no myeloproliferative neoplasm (i.e. primary myelofibrosis, systemic mastocytosis, 
polycthaemia vera, and chronic eosinophilic leukemia) or acute promyelocytic leukemia 
samples were sensitive to UNC2025. Similarly, although approximately 15% of CML 
samples were scored as sensitive, the majority (58%) had IC50 values >10μM.
UNC2025 inhibits MERTK phosphorylation in bone marrow leukemia cells
Our previous studies demonstrated inhibition of MERTK phosphorylation in bone marrow 
leukemia cells at Tmax of 0.5 hours following administration of a single 3mg/kg dose of 
UNC2025 (15). To determine the dose required to mediate >90% inhibition of MERTK 
phosphorylation over 24 hours (i.e. the minimum once daily dose to attain continuous 
MERTK inhibition), 697 B-ALL NSG xenografts were generated and bone marrow cells 
were collected after a single dose of UNC2025. Lysates were prepared and phosphorylated 
and total human MERTK levels were determined. After 24 hours, MERTK phosphorylation 
was significantly decreased by 31% and 66% in 697 cells from mice treated with 3mg/kg or 
25mg/kg UNC2025, respectively (Supplemental Figure 3). In contrast, treatment with 
75mg/kg sustained robust MERTK inhibition (>90%) over 24 hours. Based on these data, 
once daily doses of 50mg/kg and 75mg/kg were used for subsequent studies.
UNC2025 mediates minimal and manageable toxicities in mice
To evaluate toxicities associated with UNC2025, C57Bl/6 mice were treated with 75mg/kg 
UNC2025 for 24 days. Complete blood counts were determined and revealed a significant 
decrease (1.46x103/μL versus 5.37 x103/μL) in the total number of white blood cells 
(WBCs, Figure 3A). Minor alterations in the fractions of lymphocytes and granulocytes 
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were observed, indicating that all three WBC subsets were similarly affected (Figure 3B). 
Mice treated with UNC2025 also developed anemia, indicated by significant decreases in 
RBC number (61%), hemoglobin concentration (61%), and hematocrit (65%) (Figure 3C). 
The RBCs that were present appeared relatively normal, with significant but minor decreases 
in cell volume (11%) and distribution width (19%) and a corresponding increase in cellular 
hemoglobin concentration (11%). There was no significant difference in the number of 
platelets and a slight but statistically significant increase in platelet volume (7%) (Figure 
3D).
To investigate the etiology of these effects, bone marrow progenitor populations were 
analyzed by flow cytometry. There was a significant 73% decrease in bone marrow 
cellularity (Figure 3E) with decreased numbers of long-term hematopoietic stem cells (LT-
HSCs, 48%), and downstream common myeloid progenitors (CMP, 65%) and 
megakaryocyte-erythroid progenitors (MEP, 98%) (Figures 3F–G and Supplemental Figure 
4). In contrast, there was a statistically significant 96% increase in short-term hematopoietic 
stem cells (ST-HSCs, Figure 3F). Taken together, the observed increase in the number of ST-
HSCs and concomitant reductions in LT-HSCs, more differentiated hematopoietic 
progenitors, and mature blood cells suggest a developmental arrest at the ST-HSC stage.
Blood electrolytes, indicators of renal function, liver enzymes and albumin concentrations 
were also analyzed and demonstrated minimal changes, including increased sodium 
(141mM versus 154mM), decreased blood urea nitrogen (24.2mg/dL versus 18.5mg/dL), 
and increased alanine transaminase (55.3U/L versus 83.0U/L) (Supplemental Figure 5). 
Although statistically significant, relative changes of these magnitudes would not require 
alteration of chemotherapeutic doses in standard leukemia treatment protocols and are 
unlikely to be clinically relevant. Alkaline phosphatase was more dramatically increased 
(32.8U/L versus 213.4U/L). The significance of this increase is unknown, but is not usually 
a dose-limiting laboratory finding in cancer therapeutics. Albumin, a surrogate marker of 
liver function and malabsorption was not significantly changed.
UNC2025 delays disease progression and prolongs survival in MERTK-dependent 
orthotopic murine B-ALL and AML xenograft models
NSG mice were inoculated with 697 B-ALL cells expressing the firefly luciferase gene by 
tail vine injection and treated once daily with 50mg/kg or 75mg/kg UNC2025 or vehicle 
administered orally. Disease burden was determined by bioluminescence imaging and 
survival was monitored. In initial studies, treatment began one day after tumor cell 
inoculation to mimic the disease state after induction therapy. In this model, UNC2025 
mediated a statistically significant dose-dependent reduction in tumor burden relative to 
vehicle (Figures 4A and B). UNC2025 also mediated dose-dependent increases in median 
survival from 26 days after initiation of treatment in vehicle-treated mice, to 34 and 70 days 
in mice treated with 50 or 75 mg/kg UNC2025, respectively (Figure 4C). Increases in 
survival were consistent across multiple experiments (Supplemental Table 3). Interestingly, 
disease was most evident in the spleen and liver in vehicle-treated mice but was primarily 
localized to the spinal column and brain in mice treated with UNC2025, suggesting central 
nervous system involvement (Figure 4A). UNC2025 was penetrant to the brain, but at 
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reduced concentrations (~25%) relative to plasma (Supplemental Table 4) that are likely too 
low to mediate significant direct anti-leukemia effects (Figures 4A–C). To test effects of 
UNC2025 in mice with more substantial disease burden, treatment was delayed until 12 days 
after leukemia inoculation. Mean pre-treatment disease burden was not significantly 
different between groups. Disease burden was significantly decreased in mice treated with 
UNC2025 compared to vehicle (Figure 4D), leading to a two-fold increase in median 
survival, from 16 to 34 days post-treatment (Figure 4E). In multiple experiments, treatment 
with UNC2025 consistently increased survival two-fold or greater, even when very high 
disease burden was present before treatment (Supplemental Table 5). Similar results were 
observed in NSGS mice with xenografts of the MERTK-dependent NOMO-1 AML cell line. 
In this case, treatment was initiated 21 days after leukemia inoculation and increased median 
survival from 15.5 to 37 days post-treatment (Figure 4F). These data demonstrate robust 
therapeutic activity mediated by UNC2025 in vivo in ALL and AML models, irrespective of 
disease stage.
UNC2025 induces disease regression and prolongs survival in a patient-derived orthotopic 
murine AML xenograft model
To better recapitulate the biology associated with acute leukemia in humans, an orthotopic 
patient-derived xenograft model was derived. Primary MERTK-expressing AML blasts were 
injected intravenously into NSGS mice. Before initiation of treatment there was substantial 
disease burden in peripheral blood (12.58+/−2.75% blasts), spleen (182+/−48 x106 blasts) 
and bone marrow (58.61+/−4.07% blasts) (Figures 5A and B). After 21 days of treatment, 
disease burden in bone marrow and spleen was not significantly different in vehicle-treated 
mice compared to the pre-treatment cohort, but peripheral disease was dramatically 
increased (Figures 5A and B). In contrast, mice treated with 75 mg/kg UNC2025 exhibited 
significant disease regression in peripheral blood (64%), spleen (50%) and bone marrow 
(51%) relative to pre-treatment disease burden. In another experiment, peripheral disease 
burden was monitored throughout the study as an indicator of disease progression and 
survival was determined. Prior to treatment, there was substantial disease burden in blood 
(10.61+/−2.15% blasts), bone marrow (39.98+/−7.32% blasts), and spleen (37+/−0.10x106 
blasts). After only three days of treatment, a significant decrease in peripheral disease 
burden was evident in mice treated with UNC2025 (5.66+/−1.01%; Figure 5C). 
Additionally, median survival was prolonged from 19.5 to 39 days post-treatment in mice 
treated with vehicle or UNC2025, respectively (Figure 5D). Nearly identical results were 
obtained in a repeat experiment (data not shown). Thus, treatment with UNC2025 mediated 
robust therapeutic activity and was sufficient to induce disease regression and prolong 
survival in a patient-derived AML xenograft model.
UNC2025 sensitizes 697 ALL cells to treatment with methotrexate in vivo
We previously demonstrated increased sensitivity to cytotoxic chemotherapies in 697 B-
ALL cells with shRNA-mediated MERTK inhibition in vitro. To determine whether 
MERTK inhibition has a similar effect in vivo and to investigate the potential for application 
of UNC2025 in the context of current therapeutic regimens, UNC2025 was administered in 
combination with methotrexate. Mice with orthotopic 697 xenografts were randomized to 
groups with equal starting disease burden and treated with 75 mg/kg UNC2025 and/or 1 
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mg/kg methotrexate (Figure 6A). Monotherapy with UNC2025 or methotrexate decreased 
disease burden relative to vehicle-treated mice, but the combination therapy had a 
significantly greater effect than either single agent (Figures 6B and C). Similarly, treatment 
with methotrexate or UNC2025 increased median survival to 61.5 and 72 days after tumor 
inoculation, respectively, compared to 34 days in vehicle-treated mice and 103.5 days for the 
combination therapy (Figure 6D). Thus, treatment with single agents was sufficient to 
prolong survival, but the combination therapy provided a substantially greater benefit. These 
data demonstrate favorable therapeutic interactions mediated by MERTK inhibition in 
combination with chemotherapy in vivo and indicate that addition of UNC2025 to standard 
cytotoxic therapies may provide greater therapeutic benefit and/or allow for chemotherapy 
dose-reduction and decreased toxicity.
Discussion
Previous data demonstrated MERTK over-expression in a spectrum of human cancers, 
including ALL and AML (14). Additionally, shRNA-mediated MERTK inhibition in acute 
leukemia cells abrogates oncogenic phenotypes and decreases cell survival, leading to 
decreased disease burden and prolonged survival in murine xenograft models (7, 9, 10). 
While these data implicate MERTK as a therapeutic target, they do not distinguish effects of 
MERTK inhibition on leukemia engraftment versus leukemia progression in animal models. 
To investigate the therapeutic potential of MERTK inhibition, we developed MERTK-
selective TKIs and applied them in animal models. We recently reported prolonged survival 
mediated by MRX-2843 in MERTK-dependent AML models (22). Here, we describe in vivo 
application of UNC2025, in ALL and AML models in the context of existent disease with a 
more thorough characterization of impact on disease burden. UNC2025 effectively inhibited 
phosphorylation of MERTK and its known downstream intracellular targets, induced cell 
death, decreased colony-forming potential, reduced tumor cell proliferation, and in some 
cases induced polyploidy in vitro. Moreover, UNC2025 inhibited MERTK and had potent 
therapeutic activity in orthotopic acute leukemia xenograft models. Treatment with 
UNC2025 delayed disease progression in xenografts of the MERTK-dependent 697 B-ALL 
cell line and induced disease regression in the bone marrow, spleen and peripheral blood in a 
primary patient-derived AML xenograft model. Moreover, UNC2025 therapy consistently 
increased survival two-fold in three different xenograft models, even when extensive disease 
was present at initiation of treatment. While we cannot rule out the possibility that 
UNC2025-mediated anti-leukemia activity is enhanced by off-target kinase inhibition, 
several lines of evidence suggest that this is not the case. First, treatment with UNC2025 
recapitulated the effects of shRNA-mediated MERTK inhibition (7, 9, 10). In particular, 
genetic inhibition of MERTK resulted in dose-dependent increases in median survival in cell 
line derived orthotopic xenograft models of B-ALL, T-ALL, and AML and efficient MERTK 
knock-down consistently increased survival two-fold in five different models, including 
xenografts of the 697 and NOMO-1 cell lines. Additionally, treatment with UNC2025 
selectively reduced colony-forming potential in a MERTK-expressing patient sample at 
concentrations as low as 25nM while mononuclear cells isolated from human cord blood or 
marrow, which express little or no MERTK, were relatively insensitive to UNC2025, with no 
effect observed at concentrations ≤500nM. Taken together, these data demonstrate robust 
DeRyckere et al. Page 9
Clin Cancer Res. Author manuscript; available in PMC 2018 March 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
leukemia therapeutic activity mediated by a MERTK-targeted agent with potential for 
clinical application and provide rationale for further development of UNC2025 or similar 
MERTK inhibitors for treatment of acute leukemia.
Despite the therapeutic activity mediated by UNC2025 in leukemia models, mice treated 
with UNC2025 did eventually develop progressive disease, suggesting limited utility for 
UNC2025 as monotherapy, at least in the absence of the immune system. A better 
understanding of the mechanisms of resistance to UNC2025 in this context will be important 
as MERTK inhibitors progress toward clinical development. Possible mechanisms include 
activation of compensatory signaling pathways, which could be specific to select sites of 
organ infiltration such as the bone marrow or spleen (e.g. Figure 5). However, even in cases 
where the leukemia is not sensitive to MERTK inhibition alone, it may be possible to 
provide enhanced therapeutic activity by combined treatment with a MERTK inhibitor and 
standard chemotherapeutics or other targeted agents. Indeed, UNC2025 was effective in 
mice treated with methotrexate, but a combined regimen of UNC2025 and methotrexate 
mediated more effective inhibition of leukemia progression and a significant increase in 
median survival relative to either single agent. These data are consistent with previous in 
vitro studies demonstrating increased sensitivity to numerous common cytotoxic 
chemotherapies, including methotrexate, in acute leukemia cell lines with shRNA-mediated 
MERTK inhibition (7, 9). We show here that this effect translates to in vivo models, 
suggesting that co-administration of UNC2025 and cytotoxic agents may provide greater 
benefit and potentially allow chemotherapy dose reduction and decreased long-term side 
effects. Dose reduction would be particularly advantageous in pediatric and older patient 
populations.
Although MERTK is expressed in a majority of acute leukemia patient samples, studies 
investigating the degree of MERTK-dependence in patient samples have not been reported 
and we do not necessarily expect that all MERTK-expressing samples will be sensitive to 
MERTK inhibition. Thus, it will be critical to understand the relationship between incidence 
and requirement for MERTK for effective clinical application of MERTK inhibitors. Here 
we used a high-throughput assay to characterize the effects of MERTK inhibition on freshly 
isolated leukemia patient samples. A broad spectrum of sensitivity to UNC2025 was 
observed, with IC50 values ranging from 9nM to >10μM. One-third of samples were 
sensitive, indicating that a significant fraction of patients could benefit from MERTK 
inhibition, and sensitive samples were most prevalent in the AML and T-ALL subsets. Of 
particular interest was the finding that all of the FAB category M0 AML samples were 
exquisitely sensitive to UNC2025, with IC50 values <70nM. Although our analysis of this 
subset was limited to three samples, these data are encouraging given the incidence (9% of 
AMLs in adults (23)) and poor prognosis associated with minimally differentiated (M0) 
AML (24). Similarly, the T-ALL subset was particularly sensitive, with all samples 
exhibiting IC50 values less than the median and half of the samples scored as very sensitive. 
In contrast, samples with IC50 values >10μM were observed in all other subsets. In 
particular, myeloproliferative neoplasms, acute promyelocytic leukemias and CMLs were 
relatively resistant to UNC2025. Of note, AML patient samples with and without activating 
FLT3 mutations were similarly sensitive to UNC2025 and thus, anti-leukemia activity was 
not solely mediated by FLT3 inhibition in these assays and these data implicate MERTK as a 
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therapeutic target. Although we did not directly test MERTK expression levels in the 
samples analyzed here, we and others have previously demonstrated expression of MERTK 
on >80% of AML patient samples (10, 11). Thus, the observed 40% incidence of UNC2025 
sensitivity in AML samples suggests that only a subset of MERTK-expressing samples are 
dependent on MERTK function and identification of biomarkers and/or assays that can be 
used in conjunction with MERTK expression to predict response to MERTK inhibitors will 
be critical for further clinical development.
As development of MERTK inhibitors progresses toward clinical application, it will also be 
important to anticipate potential side effects. UNC2025 was well-tolerated in mice with 
minimal and manageable toxicities and was administered daily for up to 110 days with no 
dose-limiting toxicity, even in combination with methotrexate. The primary side-effects 
associated with UNC2025 treatment were anemia and leukopenia. Blood count alterations 
were accompanied by decreased bone marrow cellularity, and reduced numbers of LT-HSCs, 
CMPs, and MEPs. In contrast, ST-HSCs were increased, suggesting a developmental arrest 
or delay at this stage leading to decreased generation of more differentiated precursors and 
mature blood cells. Significant reductions in later stage progenitors have been reported in 
Flt3/Flk2 knock-out mice (25, 26) and treatment with AC220, a FLT3 TKI, is associated 
with pan-leukopenia in mice (27). Anemia and bone marrow suppression have also been 
noted in clinical trials of FLT3 TKIs (28–30). In contrast, MERTK knock-out mice exhibit 
only a moderate decrease in GMPs with no other defects in hematopoiesis (7, 31). These 
data suggest that the hematopoietic defects in UNC2025-treated mice are due, at least in 
part, to FLT3 inhibition. It is encouraging that hematopoietic defects associated with FLT3 
inhibition are reversible (27, 28). Notably, accumulation of ST-HSCs in response to 
treatment with UNC2025 may prime the bone marrow to repopulate the hematopoietic 
system once therapy is stopped. Alternatively, these cells may have undergone aberrant 
differentiation to a non-functional ST-HSC phenotype that cannot be further differentiated.
In summary, the studies presented here demonstrate robust therapeutic activity mediated by 
UNC2025 in cell culture and animal models of acute leukemia. UNC2025 also provided 
increased therapeutic benefit in combination with methotrexate, suggesting that MERTK 
inhibition may be a particularly effective therapeutic strategy in the context of cytotoxic 
chemotherapy, allowing for dose reduction and decreased toxicity. UNC2025 was effective 
in one-third of freshly isolated leukemia patient samples and our data from a small sample 
suggest that T-ALL and minimally differentiated AML subsets are particularly sensitive. The 
incidence of MERTK expression in acute leukemia and the striking and broad spectrum 
activity mediated by UNC2025 in leukemia patient samples and xenograft models make 
MERTK a particularly attractive target and the data presented here support further 
development of UNC2025 or similar inhibitors in early phase clinical trials.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Statement of Clinical Relevance
This manuscript describes characterization of UNC2025, a novel MERTK tyrosine kinase 
inhibitor, for potential use in the treatment of acute lymphoblastic and acute myeloid 
leukemias (ALL and AML, respectively). Our previous data validate MERTK as an 
oncogenic target and demonstrate roles for MERTK in chemo-resistance. Here we 
advance these findings using UNC2025, a novel orally bioavailable MERTK-targeted 
small molecule inhibitor. Treatment with UNC2025 induced apoptosis and decreased 
clonal proliferation in acute leukemia cell lines and patient samples in vitro and 
prolonged leukemia-free survival and sensitivity to cytotoxic chemotherapy in cell line 
and patient-derived xenograft models. Of note, 30% of freshly isolated patient samples 
were sensitive to UNC2025 suggesting that a large fraction of patients with acute 
leukemia could benefit from MERTK-targeted therapy. These data support continued 
development of MERTK small molecule inhibitors toward clinical application in patients 
with ALL and AML.
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Figure 1. UNC2025 inhibits p-MERTK and downstream signaling, induces apoptosis,inhibits 
proliferation and colony formation, and induces polyploidy in acute leukemia cell lines
(A) MERTK expression (~180 kDa) in the indicated cell lines was assessed by immunoblot. 
(B) Kasumi-1 AML (top panels) and 697 B-ALL (lower panels) cells were treated with 
vehicle (DMSO) or the indicated dose of UNC2025 for one hour and pervanadate 
phosphatase inhibitor was added to the cultures for three minutes to stabilize phosphorylated 
proteins. MERTK was immunoprecipitated from cell lysates and phosphorylated (denoted 
with p-) and total MERTK proteins were detected by immunoblot. (C) Kasumi-1 cells were 
treated with DMSO or the indicated dose of UNC2025 for one hour and phosphorylated and 
total STAT6, AKT and ERK1/2 downstream signaling proteins were detected by 
immunoblot. Actin is shown as a loading control. (D–E) B-ALL (697, REH), T-ALL 
(Jurkat), and AML (Kasumi-1, NOMO-1) cell lines were treated with the indicated 
concentration of UNC2025 or DMSO for 48hours, then stained with YO-PRO-1 iodide and 
propidium iodide and analyzed by flow cytometry. Alternatively, cells were fixed, 
permeabilized and cell cycle profiles as indicated by DNA content were determined by flow 
cytometry. (D) Percentages of early apoptotic and late apoptotic/dead cells are shown. Mean 
values and standard errors were derived from 3–7 independent experiments. (E) Percentages 
of cycling cells in G0/G1, S, and G2/M phases and cells with >4N DNA content (Polyploid) 
are shown. Mean values and standard errors were derived from 3 independent experiments. 
Statistically significant differences in the fractions of cells in G2/M phase or with a 
polyploid phenotype are indicated. Additional statistical data are included in Supplemental 
Table 1. (F) ALL cell lines (697, REH, Jurkat) were cultured in liquid medium with the 
indicated concentration of UNC2025 or DMSO for 48 hours and then equal numbers of 
viable cells were cultured in methylcellulose medium in the absence of UNC2025. 
Alternatively, AML cell lines (Kasumi-1, NOMO-1) were cultured in soft agar overlaid with 
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medium containing vehicle or the indicated concentration of UNC2025, without prior drug 
pre-treatment. Colonies were stained with MTT reagent after 10–21 days and counted. 
Colony numbers relative to vehicle-treated cultures are shown. Mean values and standard 
errors were derived from 3 independent experiments. (*p<0.05, **p<0.01, ***p< 0.001, 
****p< 0.0001, 1-way ANOVA)
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Figure 2. UNC2025 inhibits p-MERTK and downstream signaling and inhibits expansion of 
leukemia patient samples in culture
(A) Mononuclear cells isolated from primary AML patient sample AML-123009 were 
treated with vehicle (DMSO) or the indicated dose of UNC2025 for one hour and 
phosphorylated (denoted by p-) and total MERTK proteins were assessed as described in 
Figure 1. (B) Downstream signaling was assessed in the AML-123009 patient sample after 
one hour treatment with vehicle or UNC2025 as described in Figure 1. (C) Mononuclear 
cells isolated from the MERTK-expressing AML-123009 patient sample was treated with 
vehicle or UNC2025 for 48 hours and then cultured in methylcellulose as described in 
Figure 1. Colony numbers relative to vehicle-treated cultures are shown. Mean values and 
standard errors were derived from triplicate samples from a single experiment. (D) 
Umbilical cord blood and bone marrow mononuclear cells collected from 3 different healthy 
donors were cultured in methylcellulose medium containing vehicle or UNC2025 for 7–14 
days. Colonies were stained and counted as in Figure 1. Colony numbers relative to vehicle-
treated cultures are shown. Mean values and standard errors were derived from three 
independent experiments (**p<0.01, NS = not significant, 1-way ANOVA). (E–F) 
Mononuclear cells isolated from primary bone marrow or peripheral blood samples collected 
from patients with hematologic malignancies were cultured in 384-well plates in liquid 
media containing vehicle or UNC2025 (14nM–10μM) for 72 hours and reduction of MTS 
tetrazolium was determined as an indicator of viable cell number. Half maximal inhibitory 
concentrations (IC50) were determined by non-linear regression. IC50 values less than 
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0.24μM (indicated by light grey shading) and 0.475μM (indicated by dark grey shading) 
were scored as very sensitive and moderately sensitive, respectively. (E) Patient samples are 
shown grouped by hematologic malignancy subtype. (F) AML patient samples are shown 
grouped by French-American-British (FAB) classification on the left side of the graph and 
by molecular lesion on the right.
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Figure 3. Treatment with UNC2025 alters bone marrow progenitor populations and decreases 
white and red blood cell numbers
C57Bl/6 mice were treated with 75mg/kg UNC2025 (gray bars) or an equivalent volume of 
saline (white bars) once daily for 24 days. Bone marrow and peripheral blood were 
harvested. Complete blood counts were determined and bone marrow progenitor populations 
were analyzed by flow cytometry. (A) Peripheral white blood cell (WBC) counts. (B) 
Percentages of lymphocytes, granulocytes and monocytes in peripheral blood mononuclear 
cells. (C) Red blood cell counts and indices. (D) Platelet counts and volumes. (E) Number of 
nucleated cells in the bone marrow. (F) Numbers of stem cells and multi-potent progenitor 
cells. (G) Numbers of Lin− Sca1− cKit+ and myeloid progenitor cells. Mean values and 
standard errors are shown (n=7 or 11). (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, NS 
= not significant, unpaired t-test)
DeRyckere et al. Page 20
Clin Cancer Res. Author manuscript; available in PMC 2018 March 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. UNC2025 delays disease progression and prolongs survival in MERTK-dependent 
orthotopic ALL and AML xenograft models
(A–E) 697 B-ALL cells expressing the firefly luciferase gene were inoculated into NOD-
SCID-gamma (NSG) mice by tail vein injection. Mice were treated once daily with 50 or 75 
mg/kg UNC2025 or an equivalent volume of saline beginning one day after tumor cell 
inoculation (A–C) to model minimal residual disease (MRD) or 12 days after tumor cell 
inoculation (D–E) to model existent disease. Disease burden was determined by 
bioluminescence imaging and survival was monitored. (A) Representative bioluminescent 
images of the 697 MRD model. (B) Bioluminescence intensity over time in the 697 MRD 
model. (n=9–11, **p<0.01, ****p<0.0001, ‡ p<0.05, ‡‡‡‡ p<0.0001, 1-way ANOVA; * 
denotes comparison between saline and 75mg/kg UNC2025, ‡ denotes comparison between 
saline and 50mg/kg UNC2025). (C) Kaplan-Meier curves derived from the 697 MRD 
model. Median survival was 26, 34, and 70 days after initiation of treatment in mice treated 
with vehicle, 50mg/kg UNC2025, and 75mg/kg UNC2025, respectively (n = 9–11; log rank 
test). (D) Bioluminescence intensity over time in the 697 existent disease model. (n=5, 
**p<0.01 compared to saline, 1-way ANOVA). (E) Kaplan-Meier curves derived from the 
697 existent disease model. Median survival was 16 and 34 days after initiation of treatment 
in mice treated with vehicle and 75mg/kg UNC2025, respectively (n = 5; log rank test). (F) 
NOMO-1 AML cells were inoculated into NSG mice expressing human cytokines (NSGS) 
by tail vein injection. Mice were treated once daily with UNC2025 or an equivalent volume 
of saline beginning 21 days after tumor cell inoculation and survival was monitored. Kaplan-
Meier curves are shown demonstrating median survival of 15.5 and 37 days after initiation 
of treatment with vehicle and 75mg/kg UNC2025, respectively (n = 9–10; log rank test).
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Figure 5. UNC2025 induces disease regression and prolongs survival in an orthotopic patient-
derived AML xenograft model
NSGS mice were inoculated with mononuclear cells isolated from the MERTK-expressing 
AML-123009 primary patient sample. Once daily treatment with 75mg/kg UNC2025 or an 
equivalent volume of saline vehicle was initiated 41 days after tumor cell inoculation. 
Peripheral blood, bone marrow, and spleen were harvested and leukemic blasts (human 
CD45+) were detected by flow cytometry. Survival was monitored. (A) Percentages of 
leukemic blasts in bone marrow and peripheral blood before initiation of treatment, and 21 
days after initiation of treatment (n=6–7; 1-way ANOVA). (B) Numbers of blasts in the 
spleen before treatment and after 21 days of treatment (n=6–7; 1-way ANOVA). (C) Percent 
blasts in peripheral blood over time (n = 11–12; unpaired t-test). (D) Kaplan-Meier curves 
demonstrating median survival of 19.5 and 39 days after initiation of treatment with saline or 
UNC2025, respectively (n=11–12; log-rank test). (*p< 0.05, **p < 0.01, ****p < 0.0001, 
NS = not significant).
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Figure 6. UNC2025 provides additional therapeutic benefit in combination with methotrexate in 
vivo
697 B-ALL xenografts were generated in NSG mice as described in Figure 4. (A) Schematic 
of treatment administration. Once daily treatment with 75mg/kg UNC2025 or an equivalent 
volume of saline was initiated 12 days after tumor cell inoculation. 1mg/kg methotrexate 
(MTX) or an equivalent volume of vehicle (DMSO) was administered on two consecutive 
days per week for six weeks beginning 14 days after tumor inoculation. (B) Representative 
bioluminescent images are shown. (C) Bioluminescence intensity over time (n=10, *p<0.05, 
***p<0.001, ****p<0.0001, 1-way ANOVA; red asterisks denote comparison between 
saline and methotrexate, blue asterisks denote comparison between saline and UNC2025 
monotherapy, green asterisks denote comparison between the indicated treatment and 
combination therapy) (D) Kaplan-Meier curves are shown demonstrating median survival of 
34 days after initiation of treatment with vehicle, 61.5 days for MTX, 72 days for 75 mg/kg 
UNC2025, and 103.5 days for combination therapy (n = 10). Statistical comparisons versus 
saline are shown in gray, versus methotrexate in red, and versus UNC2025 in blue (log rank 
test).
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